Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-masked study of intravitreal bevasiranib maintenance versus continued Lucentis in neovascular AMD
2007-003042-15Phase 3Terminated
- Sponsor
- OPKO Health
- Start
- Jul 2007
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bevasiranib in age-related macular degeneration (AMD) (3 arms), sponsored by OPKO Health. Primary endpoints: Ocular safety and Efficacy non-inferiority of bevasiranib maintenance versus continued ranibizumab. Started Jul 2007; status: terminated.
02
Drugs
bevasiranib
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2007-003042-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003042-15.